Last reviewed · How we verify
quadrivalent influenza split vaccine
At a glance
| Generic name | quadrivalent influenza split vaccine |
|---|---|
| Sponsor | Jiangsu Province Centers for Disease Control and Prevention |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- Clinical Trials of Quadrivalent Influenza Vaccine (PHASE1, PHASE2)
- A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults (PHASE1)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: